Hyperparathyroidism and dialysis vintage

被引:0
作者
Chertow, GM
Plone, M
Dillon, MA
Burke, SK
Slatopolsky, E
机构
[1] Univ Calif San Francisco, Div Nephrol, Moffitt Long Hosp, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Med, UCSF Mt Zion Med Ctr, San Francisco, CA 94143 USA
[3] GelTex Pharmaceut Inc, Waltham, MA USA
[4] Washington Univ, Sch Med,Med Ctr, Barnes Jewish Hosp, Dept Internal Med,Div Renal, St Louis, MO USA
关键词
hyperparathyroidism; end-stage renal disease; hemodialysis; phosphate; calcium; vintage; cross-sectional study;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
<(Background)under bar>: Secondary hyperparathyroidism and its effects on bone and viscera are among the most important complications of end-stage renal disease. Despite its ubiquity, little is known about the treated natural history of the disorder. <(Methods)under bar>: We assembled a cohort of 310 patients with endstage renal disease on hemodialysis who were participants in one of four clinical trials of the phosphate binder sevelamer. Baseline parathyroid hormone levels were collected, and the relation between dialysis vintage and other clinical variables with parathyroid hormone were described. <(Results)under bar>: There was a direct relation between dialysis vintage and the severity of hyperparathyroidism. Other variables that were significantly associated with PTH on univariate analysis included age, African American race, Kt/V, and the serum concentrations of calcium, phosphate, and bicarbonate. Multivariable linear regression analysis yielded three significant predictors of PTH: calcium, phosphorus, and vintage (5.8% (4.0 - 7.5%) expected increase in PTH per year of vintage). The model R-2 was 0.22. <(Conclusion)under bar>: Dialysis vintage is a key determinant of the severity of secondary hyperparathyroidism. Vintage and certain laboratory variables should be considered in the evaluation of therapies aimed at modifying the treated natural history of this disorder.
引用
收藏
页码:295 / 300
页数:6
相关论文
共 17 条
[1]  
Akizawa T, 1993, Curr Opin Nephrol Hypertens, V2, P558, DOI 10.1097/00041552-199307000-00006
[2]  
BOGICEVIC M, 1989, EXP CLIN ENDOCRINOL, V92, P357
[3]   Effects of excess PTH on nonclassical target organs [J].
Bro, S ;
Olgaard, K .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 30 (05) :606-620
[4]   Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans [J].
Fliser, D ;
Franek, E ;
Fode, P ;
Stefanski, A ;
Schmitt, CP ;
Lyons, M ;
Ritz, E .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (05) :933-938
[5]   RENAL OSTEODYSTROPHY - PATHOGENESIS AND MANAGEMENT [J].
GONZALEZ, EA ;
MARTIN, KJ .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1995, 10 :13-21
[6]   Patients surviving more than 10 years on haemodialysis. The natural history of the complications of treatment [J].
Harris, SAC ;
Brown, EA .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (05) :1226-1233
[7]  
Heaf JG, 1998, J NEPHROL, V11, P203
[8]   VALUES OF INTACT SERUM PARATHYROID-HORMONE IN DIFFERENT STAGES OF RENAL-INSUFFICIENCY [J].
HELLMAN, P ;
BACKMAN, U ;
DANIELSON, BG ;
AKERSTROM, G ;
RASTAD, J ;
WIDE, L ;
LJUNGHALL, S .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1991, 25 (03) :227-232
[9]   Parathyroidectomy in patients with chronic renal failure [J].
Howard, RJ ;
Pfaff, WW .
AMERICAN JOURNAL OF SURGERY, 1998, 175 (04) :302-304
[10]  
MALLUCHE HH, 1992, KIDNEY INT, V42, pS62